N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=451 Project Breast47: Effect of an Educational Intervention
Breast Neoplasm · Primary Prevention · Risk Factors
Primary: Behavioral BC Risk With an Educational Intervention for Prevention — 8.10; 8.15 units on a scale
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Phase 2 N=257 Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
N/A N=1,007 Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer
Breast Cancer · Contralateral Breast Cancer
Primary: MRI Diagnostic Yield of Cancers in the Contralateral Breast — 30; 114; 3; 822 Participants
N/A N=8 Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms
Breast Cancer
Primary: Assess the Ability of the HD PET/CT to Predict Final Histopathologic NAC Response.
N/A N=45 ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer
Breast Cancer
Primary: Correlation of Peak Displacement (PD) for Detecting Malignancy — 4.5803; 8.628 microns — p=0.2988
N/A N=224 Breast Cancer: Feasibility of an Educational Intervention
Women's Health: Neoplasm of Breast
Primary: Feasibility of an Educational Intervention: Adherence to the Intervention — 99; 83 Participants
Phase 2 N=55 Study of Breast Cancer Prevention by Letrozole in High Risk Women
Breast Cancer
Primary: Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months — -1.5; -1.1 percentage of cells stained positive — p=0.92
N/A N=36,444 Surveillance Imaging Modalities for Breast Cancer Assessment
Breast Cancer
Primary: Number of Breast Cancers Detected — 279; 27 cancers detected
Phase 2 N=43 Neoadjuvant Treatment of Breast Cancer
Breast Cancer
Primary: Overall Clinical Response to the Dose Dense Regimen — 43 Participants
Phase 2 N=234 Intraoperative Detection of Residual Cancer in Breast Cancer
Breast Cancer
Primary: Collect Data to Refine and Verify the Tumor Detection Algorithm. — 11.3 Percentage
Phase 2 N=72 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Percent of Breast Epithelial Cells Staining Positive for Ki-67 — -1.2; -2.0 percentage of cells staining positive — p=0.71
Phase 2 N=17 Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
Breast Cancer
Primary: Number of Patients With Pathological Complete Response — 2 participants
Phase 2 N=60 Feasibility Study of Intraoperative Imaging in Breast Cancer
Breast Cancer
Primary: (Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials — 2.1; 4.7; 4.2 Ratio
N/A N=496 Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography
Breast Cancer
Primary: Detection of Breast Cancer (Sensitivity)
N/A N=1,704 Radiologic Evaluation and Breast Density (READ)
Breast Cancer
Primary: Mammogram Recall for Additional Imaging — 11.3; 12.3; 9.8 percentage of women recalled
Phase 2 N=43 Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7 · Stage IB Breast Cancer AJCC v7
Primary: Number of Participants With Residual Disease — 24 Participants
N/A N=20 Tactile Breast Imaging Sensor for Tumor Malignancy Characterization
Breast Cancer
Primary: Size Error in Millimeters — 0 milimeters
Phase 2 N=49 Neoadjuvant GW572016 to Treat Breast Cancer
Breast Cancer
Primary: Clinical Response — 3; 30; 11; 3 participants
Phase 2 N=42 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration. — -2.3 Change in % of cells positive for Ki-67
Phase 2 N=69 Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Breast Cancer
Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort
Phase 2 N=46 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Breast Neoplasms
Primary: Percent Change in Mammographic Density at 1 Year on Exemestane — -2.4 percent change from baseline
Phase 2 N=82 Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
Breast Cancer
Primary: Cardiac Toxicity of Weekly Taxol Given With Weekly Herceptin When Delivered Immediately Following Four Cycles of Standard Dose AC. — 1; 8; 3; 11 Participants
Phase 2 N=30 Denosumab and MRI Breast Imaging
Breast Cancer
Primary: Relative Change of ≥ 5% in Breast Density at 6 Months — 13; 8; 4 Participants — p=0.026
Phase 4 N=256 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer
Benign Breast Disease · Fibrocystic Disease of Breast · Fibroadenoma
Primary: Number of Participants Analysed for Reduction in Lump Size ( 60% Reduction in Lump Size Considered to be a Satisfactory Response) — 63; 61; 54; 14 participants
Phase 2 N=35 Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country
Breast Cancer · Breast Neoplasms
Primary: Number of Participants Who Were Successfully Accrued in the Study, as a Measure of Feasibility — 35 participants
Phase 2 N=23 A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
Breast Cancer · Cancer
Primary: The Number of Participants With Dose Limiting Toxicities (DLT) in the Safety Run-in Phase — 0; 2; 0 Participants
Phase 3 N=740 Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 64; 71; 70 percentage of participants